Associates in Neurology, PSC

Lexington, Kentucky 40513

0 studies enrolling now · 18 studies all time

What they study most

Alzheimer's Disease, Epilepsies, Partial, Epilepsy With Partial On-set Seizures, Migraine Disorders, Migraine With or Without Aura, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Partial Seizures, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Prevention, Stroke

Studies at this site

• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• Once-A-Day Pregabalin For Partial Seizures — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Study of Fampridine-SR Tablets in Multiple Sclerosis Patients — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial — Completed
• Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) — Status unconfirmed